What is the share price of Neuland Laboratories Ltd (NEULANDLAB) today?
The share price of NEULANDLAB as on 5th December 2025 is ₹16657. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Neuland Laboratories Ltd (NEULANDLAB) share?
The past returns of Neuland Laboratories Ltd (NEULANDLAB) share are- Past 1 week: 1.60%
- Past 1 month: -1.26%
- Past 3 months: 16.31%
- Past 6 months: 44.11%
- Past 1 year: -4.47%
- Past 3 years: 896.19%
- Past 5 years: 1418.09%
What are the peers or stocks similar to Neuland Laboratories Ltd (NEULANDLAB)?
The peers or stocks similar to Neuland Laboratories Ltd (NEULANDLAB) include:What is the dividend yield % of Neuland Laboratories Ltd (NEULANDLAB) share?
The current dividend yield of Neuland Laboratories Ltd (NEULANDLAB) is 0.07.What is the market cap of Neuland Laboratories Ltd (NEULANDLAB) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Neuland Laboratories Ltd (NEULANDLAB) is ₹21804.40 Cr as of 5th December 2025.What is the 52 week high and low of Neuland Laboratories Ltd (NEULANDLAB) share?
The 52-week high of Neuland Laboratories Ltd (NEULANDLAB) is ₹19747 and the 52-week low is ₹10190.70.What is the PE and PB ratio of Neuland Laboratories Ltd (NEULANDLAB) stock?
The P/E (price-to-earnings) ratio of Neuland Laboratories Ltd (NEULANDLAB) is 83.83. The P/B (price-to-book) ratio is 14.30.Which sector does Neuland Laboratories Ltd (NEULANDLAB) belong to?
Neuland Laboratories Ltd (NEULANDLAB) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Neuland Laboratories Ltd (NEULANDLAB) shares?
You can directly buy Neuland Laboratories Ltd (NEULANDLAB) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Neuland Laboratories Ltd
NEULANDLAB Share Price
NEULANDLAB Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
NEULANDLAB Performance & Key Metrics
NEULANDLAB Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 90.79 | 14.30 | 0.07% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.94 | 5.83 | 0.58% |
from 4 analysts
Price Upside
Earnings Growth
Rev. Growth
NEULANDLAB Company Profile
Neuland Laboratories Limited is engaged in manufacturing active pharmaceutical ingredient (API). The Company also provides custom manufacturing solutions (CMS) to develop and manufacture pharmaceutical ingredients and intermediates.
NEULANDLAB Sentiment Analysis
NEULANDLAB Sentiment Analysis
NEULANDLAB Stock Summary · November 2025
In Q2 FY26, the company achieved a remarkable 63.7% year-over-year increase in total income, primarily fueled by robust commercial CMS projects, despite facing challenges with working capital and a lengthy 155-day cycle. While management remains optimistic about long-term growth through strategic investments and operational efficiency, the CDMO sector's inherent variability necessitates a cautious approach to performance evaluation. The commitment to sustainability is evident in the development of greener processes, particularly in peptide production, alongside significant capital expenditures for expanding production capacity. However, the company must navigate the complexities of market dynamics, including raw material cost volatility and customer demand fluctuations, to sustain its improved EBITDA margins and capitalize on growth opportunities.
NEULANDLAB Stock Growth Drivers
NEULANDLAB Stock Growth Drivers
6Strong Financial Performance
Neuland Laboratories Limited reported a total income of Rs. 516 crores in Q2 FY26, marking
Investment in Growth and Capacity Expansion
The company invested Rs. 91 crores in capital expenditures for the quarter and Rs. 170.7
NEULANDLAB Stock Challenges
NEULANDLAB Stock Challenges
4Deterioration in Working Capital
The company has experienced a significant deterioration in working capital, primarily due to increased inventories
Clinical Pipeline Challenges
The company's clinical pipeline has undergone changes, with some molecules being removed from the commercial
NEULANDLAB Forecast
NEULANDLAB Forecasts
Price
Revenue
Earnings
NEULANDLAB Share Price Forecast
NEULANDLAB Share Price Forecast
All values in ₹
All values in ₹
NEULANDLAB Company Revenue Forecast
NEULANDLAB Company Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
NEULANDLAB Stock EPS (Earnings Per Share) Forecast
NEULANDLAB Stock EPS (Earnings Per Share) Forecast
All values in ₹
All values in ₹
NEULANDLAB
NEULANDLAB
Income
Balance Sheet
Cash Flow
NEULANDLAB Income Statement
NEULANDLAB Income Statement
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 580.06 | 531.94 | 670.32 | 766.60 | 953.01 | 953.16 | 1,200.95 | 1,571.12 | 1,573.75 | 1,610.22 | ||||||||||
| Raw Materials | 272.33 | 283.36 | 363.03 | 394.41 | 443.04 | 441.79 | 491.98 | 636.49 | 578.45 | 1,205.71 | ||||||||||
| Power & Fuel Cost | 25.78 | 25.95 | 26.81 | 32.75 | 39.21 | 42.21 | 48.62 | 48.72 | 50.56 | |||||||||||
| Employee Cost | 92.74 | 102.99 | 110.46 | 123.56 | 149.74 | 182.47 | 201.79 | 257.06 | 272.00 | |||||||||||
| Selling & Administrative Expenses | 39.45 | 47.35 | 46.15 | 46.42 | 73.93 | 63.21 | 80.80 | 94.84 | 108.64 | |||||||||||
| Operating & Other expenses | 42.25 | 17.33 | 62.01 | 63.68 | 84.17 | 78.78 | 96.16 | 58.89 | 143.93 | |||||||||||
| EBITDA | 107.51 | 54.96 | 61.86 | 105.78 | 162.92 | 144.70 | 281.60 | 475.12 | 420.17 | 404.51 | ||||||||||
| Depreciation/Amortization | 19.23 | 22.10 | 25.86 | 31.28 | 39.68 | 49.04 | 52.78 | 59.70 | 65.55 | 75.92 | ||||||||||
| PBIT | 88.28 | 32.86 | 36.00 | 74.50 | 123.24 | 95.66 | 228.82 | 415.42 | 354.62 | 328.59 | ||||||||||
| Interest & Other Items | 21.09 | 18.93 | 15.66 | 21.57 | 17.90 | 13.50 | 13.07 | 14.00 | 8.30 | 14.52 | ||||||||||
| PBT | 67.19 | 13.93 | 20.34 | 52.93 | 105.34 | 82.16 | 215.75 | 401.42 | 346.32 | 314.07 | ||||||||||
| Taxes & Other Items | 20.32 | 1.87 | 3.90 | 36.72 | 24.71 | 18.34 | 52.23 | 101.36 | 86.22 | 73.92 | ||||||||||
| Net Income | 46.87 | 12.06 | 16.44 | 16.21 | 80.63 | 63.82 | 163.52 | 300.06 | 260.10 | 240.15 | ||||||||||
| EPS | 52.25 | 13.47 | 15.04 | 12.60 | 62.85 | 49.74 | 127.45 | 233.88 | 202.73 | 187.18 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 2.00 | 5.00 | 5.00 | 10.00 | 14.00 | 12.00 | 12.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.16 | 0.08 | 0.10 | 0.08 | 0.06 | 0.06 | 0.06 |
NEULANDLAB Company Updates
Investor Presentation
NEULANDLAB Stock Peers
NEULANDLAB Past Performance & Peer Comparison
NEULANDLAB Past Performance & Peer Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Neuland Laboratories Ltd | 83.83 | 14.30 | 0.07% |
| Sun Pharmaceutical Industries Ltd | 39.92 | 6.02 | 0.88% |
| Torrent Pharmaceuticals Ltd | 67.21 | 16.92 | 0.84% |
| Cipla Ltd | 23.30 | 3.93 | 1.05% |
NEULANDLAB Stock Price Comparison
Compare NEULANDLAB with any stock or ETFNEULANDLAB Holdings
NEULANDLAB Shareholdings
NEULANDLAB Promoter Holdings Trend
NEULANDLAB Promoter Holdings Trend
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant
NEULANDLAB Institutional Holdings Trend
NEULANDLAB Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has decreased by 1.09%
NEULANDLAB Shareholding Pattern
NEULANDLAB Shareholding Pattern
NEULANDLAB Shareholding History
NEULANDLAB Shareholding History
Mutual Funds Invested in NEULANDLAB
Mutual Funds Invested in NEULANDLAB
No mutual funds holding trends are available
Top 5 Mutual Funds holding Neuland Laboratories Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 2.0462% | Percentage of the fund’s portfolio invested in the stock 2.27% | Change in the portfolio weight of the stock over the last 3 months 0.52% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 13/85 (+6) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.2595% | Percentage of the fund’s portfolio invested in the stock 1.66% | Change in the portfolio weight of the stock over the last 3 months -0.00% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 64/115 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.6997% | Percentage of the fund’s portfolio invested in the stock 2.53% | Change in the portfolio weight of the stock over the last 3 months 1.59% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 4/101 (+35) |
Compare 3-month MF holding change on Screener
smallcases containing NEULANDLAB stock
smallcases containing NEULANDLAB stock
Looks like this stock is not in any smallcase yet.
NEULANDLAB Events
NEULANDLAB Events
NEULANDLAB Dividend Trend
NEULANDLAB has increased or maintained dividend levels over the last 5 years
Current dividend yield is 0.07%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹0.71 every year
Dividends
Corp. Actions
Announcements
Legal Orders
NEULANDLAB Dividend Trend
NEULANDLAB has increased or maintained dividend levels over the last 5 years
Current dividend yield is 0.07%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹0.71 every year
NEULANDLAB Upcoming Dividends
NEULANDLAB Upcoming Dividends
No upcoming dividends are available
NEULANDLAB Past Dividends
NEULANDLAB Past Dividends
Cash Dividend
Ex DateEx DateJul 18, 2025
Dividend/Share
₹12.00
Ex DateEx Date
Jul 18, 2025
Cash Dividend
Ex DateEx DateJul 12, 2024
Dividend/Share
₹14.00
Ex DateEx Date
Jul 12, 2024
Cash Dividend
Ex DateEx DateJul 11, 2023
Dividend/Share
₹10.00
Ex DateEx Date
Jul 11, 2023
Cash Dividend
Ex DateEx DateJul 14, 2022
Dividend/Share
₹5.00
Ex DateEx Date
Jul 14, 2022
Cash Dividend
Ex DateEx DateJun 29, 2021
Dividend/Share
₹3.00
Ex DateEx Date
Jun 29, 2021
NEULANDLAB Stock News & Opinions
NEULANDLAB Stock News & Opinions
On a quarter-on-quarter (QoQ) basis, the company's net profit zoomed 596.76%, while revenue rose 75.67% in Q2 FY26. Profit before tax (PBT) soared 161.92% YoY and 636.71% QoQ to Rs 636.71 crore in Q2 FY26. During the quarter, EBITDA stood at Rs 156.9 crore, registering growth of 138.80% compared with Rs 65.7 crore posted in the same quarter last year. EBITDA margin improved 960 bps to 30.40% in Q2 FY26 as against 20.80% in Q2 FY25. Total expenses jumped 45.59% to Rs 386.64 crore in Q2 FY26, compared with Rs 265.75 crore in Q2 FY25. The cost of material consumed stood at Rs 227.64 crore (up 70.94% YoY), employee benefit expenses were at Rs 80.37 crore (up 28.43% YoY), finance cost stood at Rs 5.17 crore (up 387.74% YoY), while manufacturing expenses stood at Rs 45.96 crore (up 8.68% YoY) during the period under review. Sucheth Davuluri, vice-chairman and chief executive officer of the company, said, 'The record high revenue this quarter driven by CMS commercial projects led to the operating leverage reflected in the EBITDA margins, and we expect this momentum to continue through the rest of the year. Given the investments we are making, Neuland is well positioned to take advantage of the number of growth opportunities available to us in both the CDMO and the generic APIs space. Customer interest in Neuland's capabilities continues to be on the rise as we see increased engagement with a diverse range of customers. Our reputation and track record as an agile partner is enabling not just new business but also a greater share of business from existing customers. Our investments are going according to plan and helping to further differentiate Neuland as a partner of choice.' Neuland Laboratories is a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates, and custom manufacturing solutions to customers in approximately 80 countries.Powered by Capital Market - Live
Net profit of Neuland Laboratories rose 194.91% to Rs 96.85 crore in the quarter ended September 2025 as against Rs 32.84 crore during the previous quarter ended September 2024. Sales rose 65.45% to Rs 514.27 crore in the quarter ended September 2025 as against Rs 310.84 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales514.27310.84 65 OPM %30.2520.02 - PBDT151.9865.50 132 PBT129.4449.42 162 NP96.8532.84 195 Powered by Capital Market - Live
India Cements Ltd, Five-Star Business Finance Ltd, Sagility Ltd, Endurance Technologies Ltd are among the other stocks to see a surge in volumes on BSE today, 30 October 2025.Neuland Laboratories Ltd registered volume of 20530 shares by 10:47 IST on BSE, a 16.61 fold spurt over two-week average daily volume of 1236 shares. The stock rose 2.40% to Rs.15,743.55. Volumes stood at 1163 shares in the last session.India Cements Ltd registered volume of 88566 shares by 10:47 IST on BSE, a 9.86 fold spurt over two-week average daily volume of 8985 shares. The stock rose 5.10% to Rs.411.00. Volumes stood at 13842 shares in the last session.Five-Star Business Finance Ltd notched up volume of 20.84 lakh shares by 10:47 IST on BSE, a 9.85 fold spurt over two-week average daily volume of 2.12 lakh shares. The stock rose 8.14% to Rs.652.50. Volumes stood at 14.42 lakh shares in the last session.Sagility Ltd registered volume of 223.05 lakh shares by 10:47 IST on BSE, a 8.89 fold spurt over two-week average daily volume of 25.10 lakh shares. The stock rose 9.96% to Rs.55.98. Volumes stood at 57.99 lakh shares in the last session.Endurance Technologies Ltd notched up volume of 31455 shares by 10:47 IST on BSE, a 6.32 fold spurt over two-week average daily volume of 4978 shares. The stock rose 0.21% to Rs.2,850.90. Volumes stood at 13535 shares in the last session.Powered by Capital Market - Live
Neuland Laboratories will hold a meeting of the Board of Directors of the Company on 7 November 2025.Powered by Capital Market - Live
Net profit of Neuland Laboratories declined 85.80% to Rs 13.90 crore in the quarter ended June 2025 as against Rs 97.87 crore during the previous quarter ended June 2024. Sales declined 33.41% to Rs 292.75 crore in the quarter ended June 2025 as against Rs 439.60 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales292.75439.60 -33 OPM %11.7828.06 - PBDT37.76125.49 -70 PBT17.57109.21 -84 NP13.9097.87 -86 Powered by Capital Market - Live
Neuland Laboratories will hold a meeting of the Board of Directors of the Company on 31 July 2025.Powered by Capital Market - Live
Ola Electric Mobility Ltd, Anand Rathi Wealth Ltd, Castrol India Ltd, Piramal Enterprises Ltd are among the other stocks to see a surge in volumes on NSE today, 14 July 2025.Neuland Laboratories Ltd clocked volume of 8.19 lakh shares by 14:14 IST on NSE, a 13.83 times surge over two-week average daily volume of 59191 shares. The stock gained 13.57% to Rs.13,970.00. Volumes stood at 74664 shares in the last session.Ola Electric Mobility Ltd witnessed volume of 4281.51 lakh shares by 14:14 IST on NSE, a 11.24 times surge over two-week average daily volume of 381.06 lakh shares. The stock increased 13.69% to Rs.45.25. Volumes stood at 286.32 lakh shares in the last session.Anand Rathi Wealth Ltd saw volume of 21.36 lakh shares by 14:14 IST on NSE, a 8.02 fold spurt over two-week average daily volume of 2.66 lakh shares. The stock increased 8.27% to Rs.2,394.70. Volumes stood at 17.1 lakh shares in the last session.Castrol India Ltd notched up volume of 225.99 lakh shares by 14:14 IST on NSE, a 7.74 fold spurt over two-week average daily volume of 29.18 lakh shares. The stock rose 1.91% to Rs.224.10. Volumes stood at 13.1 lakh shares in the last session.Piramal Enterprises Ltd witnessed volume of 40.33 lakh shares by 14:14 IST on NSE, a 6.27 times surge over two-week average daily volume of 6.44 lakh shares. The stock increased 5.10% to Rs.1,279.60. Volumes stood at 25.09 lakh shares in the last session.Powered by Capital Market - Live
Anand Rathi Wealth Ltd, Piramal Enterprises Ltd, Vodafone Idea Ltd and Tega Industries Ltd are among the other gainers in the BSE's 'A' group today, 14 July 2025.Neuland Laboratories Ltd spiked 10.08% to Rs 13546.9 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 56484 shares were traded on the counter so far as against the average daily volumes of 2317 shares in the past one month. Anand Rathi Wealth Ltd soared 8.18% to Rs 2392.4. The stock was the second biggest gainer in 'A' group. On the BSE, 34271 shares were traded on the counter so far as against the average daily volumes of 21553 shares in the past one month. Piramal Enterprises Ltd surged 6.18% to Rs 1291.75. The stock was the third biggest gainer in 'A' group. On the BSE, 1.21 lakh shares were traded on the counter so far as against the average daily volumes of 14320 shares in the past one month. Vodafone Idea Ltd advanced 5.87% to Rs 7.58. The stock was the fourth biggest gainer in 'A' group. On the BSE, 411.08 lakh shares were traded on the counter so far as against the average daily volumes of 593.47 lakh shares in the past one month. Tega Industries Ltd gained 5.80% to Rs 1785.05. The stock was the fifth biggest gainer in 'A' group. On the BSE, 9399 shares were traded on the counter so far as against the average daily volumes of 4569 shares in the past one month. Powered by Capital Market - Live
Petronet LNG Ltd, Sterling & Wilson Renewable Energy Ltd, Dr Lal Pathlabs Ltd, HFCL Ltd are among the other stocks to see a surge in volumes on BSE today, 09 July 2025.Neuland Laboratories Ltd registered volume of 4783 shares by 10:46 IST on BSE, a 3.09 fold spurt over two-week average daily volume of 1548 shares. The stock rose 2.47% to Rs.11,962.55. Volumes stood at 1249 shares in the last session.Petronet LNG Ltd registered volume of 8.3 lakh shares by 10:46 IST on BSE, a 2.62 fold spurt over two-week average daily volume of 3.17 lakh shares. The stock rose 0.25% to Rs.305.80. Volumes stood at 47163 shares in the last session.Sterling & Wilson Renewable Energy Ltd notched up volume of 3.47 lakh shares by 10:46 IST on BSE, a 2.33 fold spurt over two-week average daily volume of 1.49 lakh shares. The stock rose 4.86% to Rs.320.30. Volumes stood at 99122 shares in the last session.Dr Lal Pathlabs Ltd recorded volume of 13671 shares by 10:46 IST on BSE, a 2.13 times surge over two-week average daily volume of 6422 shares. The stock gained 3.85% to Rs.2,991.30. Volumes stood at 4213 shares in the last session.HFCL Ltd witnessed volume of 8.83 lakh shares by 10:46 IST on BSE, a 2 times surge over two-week average daily volume of 4.41 lakh shares. The stock increased 0.23% to Rs.83.28. Volumes stood at 6.44 lakh shares in the last session.Powered by Capital Market - Live
Neuland Laboratories announced that the 41th Annual General Meeting(AGM) of the company will be held on 30 July 2025.Powered by Capital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 15.47%, vs industry avg of 10.03%
Over the last 5 years, market share increased from 0.3% to 0.37%
Over the last 5 years, net income has grown at a yearly rate of 74.21%, vs industry avg of 20.02%